Surviving apoptosis after administration of a drug triggered a previously unknown evolutionary process that gave tumor cells greater resistance to subsequent therapies. A cancer cell that does not die gets stronger. Cancer reappears with those cells that escape death thanks to a mechanism that, at the same time, offers a potential therapeutic target. According to a study led by St. Jude Children's Research Hospital in collaboration with the University of Glasgow and University of Oxford, the alternative to the cell death program is a stress response pathway that generates a persister cell phenotype not described before. Read More
Astellas Pharma Inc. has described new quinazoline GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. It inhibited 3D anchorage-independent proliferation of KRAS(G12D) mutant-positive AsPC-1 cancer cells (IC50 = 23 nM) in Celltiter-Glo assays. Read More
Janssen Pharmaceutica NV has synthesized new macrocyclic compounds acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors reported to be useful for the treatment of cancer. Read More
The National Cancer Center of Japan and Tokyo University of Science have patented M-COPA analogues reported to be useful for the treatment of cancer. Read More
H-Cyte Inc. has completed its acquisition of Jantibody, a novel cancer immunotherapeutic agent that has demonstrated promising efficacy in controlling ovarian cancer and mesothelioma in preclinical models. Read More
The interaction of immune checkpoints, such as programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4), with their ligands leads to T-cell deactivation, allowing cancer cells to escape from the immune system. Read More
Pulmonary hypertension (PH) is characterized by persistent increases of pulmonary arterial pressure that can lead in the long term to right ventricular failure. Read More
Kuria Therapeutics Inc. has closed its first fundraising round to support ongoing preclinical development activities ahead of a planned series A raise. Read More
Researchers from Roche Holding AG disclosed the discovery and preclinical evaluation data for RG-7774 (vicasinabin), a novel cannabinoid CB2 receptor (CB2R) agonist being developed for the treatment of diabetic retinopathy (DR). Read More
Researchers from Boehringer Ingelheim Pharma GmbH & Co. KG presented preclinical data for BI-456906, a novel long-acting glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, currently in phase II development in patients with obesity and nonalcoholic steatohepatitis (NASH). Read More
Quince Therapeutics Inc. (formerly Novosteo Inc.) has presented data on NOV-004, a construct that delivers abaloparatide therapeutic agent into the fracture site, designed for the treatment of osteogenesis imperfecta.
Autobahn Therapeutics Inc. has closed a US$32.7 million financing to support the company's continued work in the treatment of central nervous system (CNS) disorders and the advancement of ABX-002 through phase I and into phase II proof-of-concept studies for treatment-resistant depression (TRD). Read More
